Aadi, LLC   Report issue

For profit Phase 1 Phase 2
Founded: Pacific Palisades CA United States (2011)

Organization Overview

First Clinical Trial
2014
NCT02009332
First Marketed Drug
2021
sirolimus (rapamune)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

AADI | Aadi Bioscience, Inc. | Aadi, LLC

Active Ingredients

Marketed Drugs (1)

sirolimus (rapamune) (2021)

Drugs in Phase 2 Trials (11)

Key: Aadi, LLC (7) Acquired (4)

akb-9778 (7 trials)

bevacizumab (avastin) (1 trial)

latanoprost (xalatan) (1 trial)

lomustine (1 trial)

marizomib (1 trial)

nivolumab (opdivo) (1 trial)

ranibizumab (lucentis) (1 trial)

rapamycin (6 trials)

razuprotafib (1 trial)

sirolimus (rapamune) (7 trials)

temozolomide (temodar) (1 trial)

Drugs in Phase 1 Trials (3)

Key: Aadi, LLC (2) Acquired (1)

akb-4924 (1 trial)

pomalidomide (pomalyst) (1 trial)

urea (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Chordoma (Phase 2)

Colorectal Neoplasms (Phase 2)

Drug Resistant Epilepsy (Phase 1)

Epilepsy (Phase 1)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Hypertension (Phase 1)

Hypertension, Pulmonary (Phase 1)

Leigh Disease (Phase 2)

Lung Neoplasms (Phase 2)

Multiple Myeloma (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Neuroendocrine Tumors (Phase 2)

Perivascular Epithelioid Cell Neoplasms (Phase 2)

Sarcoma (Phase 2)

Sarcoma, Ewing (Phase 2)

Syndrome (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 22
  • # of Trial APIs: 14